CN101647950A - 一种治疗高血压、高血脂的中药制剂及其制备方法 - Google Patents
一种治疗高血压、高血脂的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN101647950A CN101647950A CN200810139167A CN200810139167A CN101647950A CN 101647950 A CN101647950 A CN 101647950A CN 200810139167 A CN200810139167 A CN 200810139167A CN 200810139167 A CN200810139167 A CN 200810139167A CN 101647950 A CN101647950 A CN 101647950A
- Authority
- CN
- China
- Prior art keywords
- accounts
- preparation
- rhizoma polygonati
- hyperlipidemia
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 15
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 18
- 239000000706 filtrate Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 238000012856 packing Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000007963 capsule composition Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000004518 granules dosage form Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 208000031971 Yin Deficiency Diseases 0.000 abstract description 4
- 208000002173 dizziness Diseases 0.000 abstract description 4
- 241000411851 herbal medicine Species 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 2
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 2
- 244000182216 Mimusops elengi Species 0.000 abstract 2
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 2
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 2
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 4
- 239000010282 Emodin Substances 0.000 description 4
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 4
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 4
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 235000014786 phosphorus Nutrition 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical class [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CBOKHFLBNZMMAA-UHFFFAOYSA-N Emodin anthrone Natural products OC1=CC(O)=CC2=CC3=CC(C)=CC(O)=C3C(O)=C21 CBOKHFLBNZMMAA-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000029312 Muscular tumor Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- LAJSXCAVRQXZIO-UHFFFAOYSA-N emodin anthrone Chemical compound C1=C(O)C=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O LAJSXCAVRQXZIO-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及药物制剂,具体的说是一种以中草药为原料,治疗肝肾阴虚,头晕目昏,以及高血脂症及高血压、冠心病的辅助药物,它包括何首乌、枸杞子、黄精、山楂、决明子,其生产工艺包括:(1)将何首乌、枸杞子、黄精、山楂、决明子按照质量百分比均匀混合,放入水中煎煮2次,第一次1.5小时,第二次煎煮0.5个小时,分别制备2次滤液,备用;(2)将2次制备的滤液混合,浓缩液干燥得干燥粉末,包装,本发明药物为纯中药制剂,具有无毒副作用,疗程短,治愈率高,无复发,制备方法简单,治疗费用低的优点。
Description
技术领域:
本发明涉及药物制剂,具体的说是一种以中草药为原料,治疗肝肾阴虚,头晕目昏,以及高血脂症及高血压、冠心病的辅助药物。
背景技术:
目前,对高血脂的控制主要以西药为主,用药的同时也带来严重的毒副作用,如血脂紊乱,肝肾功能损害等。而且一旦服药则终身服药。高血脂人群中,很大一部分因惧怕服药产生的毒副作用(尤其是中老年高血脂患者),而使高血脂得不到控制,造成悲剧的发生。现在,人们经常使用的将血脂产品进行医疗、保健。单纯性血清总胆固醇增高为主的患者常选含洛伐他汀之类的产品,但是某些产品产期服用可引起肌瘤、转氨酶升高、头痛、胃肠道不适甚至影响肝功能。
发明内容:
本发明的目的就是提供一种以中草药为原料,治疗肝肾阴虚,头晕目昏,以及高血脂症及高血压、冠心病的辅助药物及其制备方法。
本发明是通过如下技术方案实现的:
一种治疗高血压、高血脂的中药制剂及其制备方法,其特征在于它包括何首乌、枸杞子、黄精、山楂、决明子,各组分的质量百分比分别为何首乌占20%-25%,枸杞子占20%-25%,黄精占28%-33%,山楂占14%-18%,决明子占0.4%-0.6%,各组分的质量百分比之和为100%,本发明中草药组合物的优选质量百分比分别为何首乌占23.8%,枸杞子占23.8%,黄精占31.8%,山楂占15.9%,决明子占0.47%,本发明组合物可加入辅料制备成多种药物剂型,包括胶囊剂型、片剂剂型、颗粒冲剂剂型中任何一种,本发明的生产工艺包括:(1)将何首乌、枸杞子、黄精、山楂、决明子按照质量百分比均匀混合,放入水中煎煮2次,第一次1.5小时,第二次煎煮0.5个小时,分别制备2次滤液,备用;(2)将2次制备的滤液混合,浓缩液干燥得干燥粉末,包装。
本配方中的中草药药性如下:何首乌含有蒽醌类的大黄素、大黄酚、大黄酸、大黄素甲醚、大黄酚蒽酮、淀粉、粗脂肪、卵磷脂等成分。中医中药理论认为,何首乌性味苦、甘、涩,微温,具有补肝、益肾、养血、祛风等功效,适用于肝肾阴亏、须发早白、血虚头晕、腰膝酸软、筋骨酸痛、遗精、崩带、久痢、慢性肝炎、痈肿、瘰疬、肠风、痔疮、红斑狼疮等病症。狗杞子是一味常用的补肝益肾中药,其色鲜红,其味香甜。现代医学研究证实其含有甜菜硷、多糖、粗脂肪、粗蛋白、胡萝卜素、维生素A、维生素C、维生素B1、维生素B2及钙、磷、铁、锌、锰、亚油酸等营养成分,对造血功能有促进作用,还能抗衰老、抗突变、抗肿瘤、抗脂肪肝及降血糖等作用。黄精以根茎入药。具有补气养阴,健脾,润肺,益肾功能。用于治疗脾胃虚弱,体倦乏力,口干食少,肺虚燥咳,精血不足,内热消渴等症。山楂含多种维生素、酒石酸、柠檬酸、山楂酸、苹果酸等,还含有黄铜类、内酯、糖类、蛋白质、脂肪和钙、磷、铁等矿物质,所含的解脂酶能促进脂肪类食物的消化。促进胃液分泌和增加胃内酶素等功能。中医认为,山楂具有消积化滞、收敛止痢、活血化淤等功效。主治饮食积滞、胸膈痞满、疝气血淤闭经等症。山楂中含有山萜类及黄铜类等药物成分,具有显著的扩张血管及降压作用,有增强心肌、抗心律不齐、调节血脂及胆固醇含量的功能。决明子除含有糖类、蛋白质、脂肪外,还含甾体化合物、大黄酚、大黄素等,还有人体必需的微量元素铁、锌、锰、铜、镍、钴、钼等。所含大黄素、大黄酸对人体有平喘、利胆、保肝、降压功效,并有一定抗菌、消炎作用。其中大黄素葡萄糖甙、大黄素蒽酮、大黄素甲醚,具有降低血清胆固醇和强心作用。决明子素具有a-羟基,可与金属素合成络合物,对金属元素吸收有很大影响。
本发明药物为纯中药制剂,具有无毒副作用,疗程短,治愈率高,无复发,制备方法简单,治疗费用低的优点。
具体实施方式:
实施例1:一种治疗高血压、高血脂的中药制剂及其制备方法,其特征在于它包括何首乌、枸杞子、黄精、山楂、决明子,各组分的质量百分比分别为何首乌占20%-25%,枸杞子占20%-25%,黄精占28%-33%,山楂占14%-18%,决明子占0.4%-0.6%,各组分的质量百分比之和为100%,其生产工艺包括:(1)将何首乌、枸杞子、黄精、山楂、决明子按照上述质量百分比均匀混合,放入水中煎煮2次,第一次1.5小时,第二次煎煮0.5个小时,分别制备2次滤液,备用;(2)将2次制备的滤液混合,浓缩液干燥得干燥粉末,包装。
实施例2:一种治疗高血压、高血脂的中药制剂及其制备方法,其特征在于何首乌、枸杞子、黄精、山楂、决明子,各组分的质量百分比分别为何首乌占23.8%,枸杞子占23.8%,黄精占31.8%,山楂占15.9%,决明子占0.47%,其生产工艺包括:(1)将何首乌、枸杞子、黄精、山楂、决明子按照上述质量百分比均匀混合,放入水中煎煮2次,第一次1.5小时,第二次煎煮0.5个小时,分别制备2次滤液,备用;(2)将2次制备的滤液混合,浓缩液干燥得干燥粉末,包装。
Claims (4)
1、一种治疗高血压、高血脂的中药制剂及其制备方法,其特征在于它包括何首乌、枸杞子、黄精、山楂、决明子,各组分的质量百分比分别为何首乌占20%-25%,枸杞子占20%-25%,黄精占28%-33%,山楂占14%-18%,决明子占0.4%-0.6%,各组分的质量百分比之和为100%。
2、根据权利要求1所述的一种治疗高血压、高血脂的中药制剂及其制备方法,其特征在于何首乌、枸杞子、黄精、山楂、决明子,各组分的质量百分比分别为何首乌占23.8%,枸杞子占23.8%,黄精占31.8%,山楂占15.9%,决明子占0.47%。
3、根据权利要求1或2所述的一种治疗高血压、高血脂的中药制剂及其制备方法,其特征在于该组合物加入辅料可制备成多种药物剂型,包括胶囊剂型、片剂剂型、颗粒冲剂剂型中任何一种。
4、根据权利要求1或2所述的一种治疗高血压、高血脂的中药制剂及其制备方法,其生产工艺包括:
(1)将何首乌、枸杞子、黄精、山楂、决明子按照质量百分比均匀混合,放入水中煎煮2次,第一次1.5小时,第二次煎煮0.5个小时,分别制备2次滤液,备用;
(2)将2次制备的滤液混合,浓缩液干燥得干燥粉末,包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810139167A CN101647950A (zh) | 2008-08-15 | 2008-08-15 | 一种治疗高血压、高血脂的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810139167A CN101647950A (zh) | 2008-08-15 | 2008-08-15 | 一种治疗高血压、高血脂的中药制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101647950A true CN101647950A (zh) | 2010-02-17 |
Family
ID=41670348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810139167A Pending CN101647950A (zh) | 2008-08-15 | 2008-08-15 | 一种治疗高血压、高血脂的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101647950A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102198197A (zh) * | 2011-05-16 | 2011-09-28 | 高向东 | 一种治疗面积型胆固醇增高症的中药制备方法 |
CN102319357A (zh) * | 2011-08-16 | 2012-01-18 | 浙江维康药业有限公司 | 一种降脂灵分散片及其制备工艺 |
-
2008
- 2008-08-15 CN CN200810139167A patent/CN101647950A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102198197A (zh) * | 2011-05-16 | 2011-09-28 | 高向东 | 一种治疗面积型胆固醇增高症的中药制备方法 |
CN102319357A (zh) * | 2011-08-16 | 2012-01-18 | 浙江维康药业有限公司 | 一种降脂灵分散片及其制备工艺 |
CN102319357B (zh) * | 2011-08-16 | 2012-11-14 | 浙江维康药业有限公司 | 一种降脂灵分散片及其制备工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101513437B (zh) | 一种抗疲劳中药组合物及其制备方法 | |
CN101983702A (zh) | 一种治疗胃虚的中药组合物及其制备方法 | |
CN104940740A (zh) | 一种治疗多囊卵巢综合征的中药组合物及其制备方法 | |
KR101002774B1 (ko) | 생약재를 주재로 한 환제 정력보강식품 및 그 제조방법 | |
CN102512615A (zh) | 一种用于癌症恢复期的中药组合物 | |
CN104971215A (zh) | 一种治疗脾虚胃弱型慢性胃炎的中药组合物及其制备方法 | |
CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN101152359A (zh) | 一种保健药酒及其制造方法 | |
CN104998168A (zh) | 一种补血益气复方中药含片及其制备工艺 | |
CN103784918A (zh) | 一种治疗马属动物反胃吐草的药物组合 | |
CN104984296A (zh) | 一种治疗女性更年期综合症的药物组合物及其制备方法 | |
CN101647950A (zh) | 一种治疗高血压、高血脂的中药制剂及其制备方法 | |
CN104258359A (zh) | 一种用于治疗妊娠反应的中药组合物及其制剂的制备方法 | |
CN106085765A (zh) | 一种健脾润肺养生酒及其制备方法 | |
CN103212044B (zh) | 一种治疗心血管疾病的中药组合物 | |
CN106138974A (zh) | 一种改善气虚体质的药物组合物和一种药砖及其制备方法 | |
CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
CN105362629A (zh) | 一种含有杜仲的治疗女性更年期综合症的药物组合物及其制备方法 | |
CN103705831B (zh) | 一种治疗绝经前后诸证的药物组合物及其制备方法 | |
CN102266540B (zh) | 一种用于治疗便秘的中药 | |
CN101019979B (zh) | 一种促进乳汁分泌的保健品 | |
CN106880794A (zh) | 一种消食健脾脐疗贴及其制备方法 | |
CN106606587A (zh) | 一种养血安神药物组合物 | |
CN104784547A (zh) | 对放疗具有增效作用的中药组合物及制备方法 | |
CN104888091A (zh) | 一种治疗肠型急性放射病的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Shaohua Document name: Notification of Publication of the Application for Invention |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100217 |